trial

Ketamine Challenge Study With JNJ-40411813

NCTId NCT01101659
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 40 (actual)
Sponsored by Johnson & Johnson
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2010-02
Primary completion
—
Eligibility
MALE · 18 Years · 45 Years

Interventions & indications

Drugs
JNJ-40411813Ketamine

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
40
Phase
PHASE1
Status
COMPLETED
relationships
The graph out of here
drug
JNJ-40411813
drug
Ketamine
drug
lead_sponsor
Johnson & Johnson
company
indication
Perceptual Disorders
indication
Confusion
indication
Perceptual Disorders
indication